The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

Arancha Prada-Villaverde, Jesus Esquivel, Andrew M. Lowy, Maurie Markman, Terence Chua, Joerg Pelz, Dario Baratti, Joel M. Baumgartner, Richard Berri, Pedro Bretcha-Boix, Marcello Deraco, Guillermo Flores-Ayala, Olivier Glehen, Alberto Gomez-Portilla, Santiago González-Moreno, Martin Goodman, Evgenia Halkia, Shigeki Kusamura, Mecker Moller, Guillaume PassotMarc Pocard, George Salti, Armando Sardi, Maheswari Senthil, John Spiliotis, Juan Torres-Melero, Kiran Turaga, Richard Trout

Research output: Contribution to journalArticle

75 Scopus citations

Abstract

BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are gaining acceptance as treatment for selected patients with colorectal cancer with peritoneal carcinomatosis (CRCPC). Tremendous variations exist in the HIPEC delivery.

METHODS: The American Society of Peritoneal Surface Malignancies (ASPSM) examined the overall survival in patients with CRCPC who underwent a complete cytoreduction and HIPEC with Oxaliplatin vs. Mitomycin C (MMC), stratifying them by the Peritoneal Surface Disease Severity Score (PSDSS).

RESULTS: Median overall survival (OS) of 539 patients with complete cytoreduction was 32.6 months, 32.7 months for the MMC group and 31.4 months for the Oxaliplatin group (P = 0.925). However, when stratified by PSDSS, median OS rates in PSDSS I/II patients were 54.3 months in those receiving MMC vs. 28.2 months in those receiving oxaliplatin (P = 0.012), whereas in PSDSS III/IV patients, median OS rates were 19.4 months in those receiving MMC vs. 30.4 months in those receiving Oxaliplatin (P = 0.427).

CONCLUSION: These data suggest that MMC might be a better agent for HIPEC delivery than Oxaliplatin in patients with CRCPC, favorable histologies and low burden of disease (PSDSS I/II) undergoing complete cytoreduction. Prospective studies are warranted, which stratify patients by their PSDSS and randomize them to HIPEC with MMC vs. Oxaliplatin.

Original languageEnglish
Pages (from-to)779-785
Number of pages7
JournalJournal of Surgical Oncology
Volume110
Issue number7
DOIs
StatePublished - Dec 1 2014

    Fingerprint

Keywords

  • colorectal cancer with peritoneal carcinomatosis
  • cytoreductive surgery
  • hyperthermic intraperitoneal chemotherapy (HIPEC)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M., Chua, T., Pelz, J., Baratti, D., Baumgartner, J. M., Berri, R., Bretcha-Boix, P., Deraco, M., Flores-Ayala, G., Glehen, O., Gomez-Portilla, A., González-Moreno, S., Goodman, M., Halkia, E., Kusamura, S., Moller, M., ... Trout, R. (2014). The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Journal of Surgical Oncology, 110(7), 779-785. https://doi.org/10.1002/jso.23728